JPH0390030A - Calcium preparation - Google Patents
Calcium preparationInfo
- Publication number
- JPH0390030A JPH0390030A JP1226216A JP22621689A JPH0390030A JP H0390030 A JPH0390030 A JP H0390030A JP 1226216 A JP1226216 A JP 1226216A JP 22621689 A JP22621689 A JP 22621689A JP H0390030 A JPH0390030 A JP H0390030A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- carbonate
- xylitol
- salt
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000011575 calcium Substances 0.000 title claims abstract description 41
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims description 27
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 21
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000811 xylitol Substances 0.000 claims abstract description 16
- 235000010447 xylitol Nutrition 0.000 claims abstract description 16
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 16
- 229960002675 xylitol Drugs 0.000 claims abstract description 16
- 150000007524 organic acids Chemical class 0.000 claims abstract description 10
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 3
- 239000011668 ascorbic acid Substances 0.000 abstract description 2
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 2
- 229960005070 ascorbic acid Drugs 0.000 abstract description 2
- 239000001569 carbon dioxide Substances 0.000 abstract description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract description 2
- 238000005187 foaming Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 150000005323 carbonate salts Chemical class 0.000 abstract 3
- 238000001816 cooling Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000003826 tablet Substances 0.000 description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000008187 granular material Substances 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960005337 lysine hydrochloride Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940034055 calcium aspartate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】 [産業上の利用分野] 本発明は、服用感の良いカルシウム製剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a calcium preparation that is comfortable to take.
〔従来の技術]
国民栄養調査によると、今日、各栄養素摂取量はいずれ
も平均所要量を上回っているのに、カルシウムについて
は1日600ngの所要量に対して553I1gの摂取
量と、低い値に留っている。そのためカルシウム欠乏症
(骨病変)の危険が日本人全体にあるといってよい。特
に1日の所要量が多い妊産婦、授乳婦、成長期の子供や
、カルシウムの吸収力の弱い老人などは、カルシウム欠
乏症の予防または治療のため、カルシウム製剤の常用が
必要となる。[Prior art] According to the National Nutrition Survey, today the intake of each nutrient exceeds the average required amount, but the intake of calcium is low at 553I1g per day compared to the required amount of 600ng. It remains in Therefore, it can be said that all Japanese people are at risk of calcium deficiency (bone lesions). In particular, pregnant women, nursing mothers, growing children, and elderly people who require a large amount of calcium per day, such as the elderly who have a weak ability to absorb calcium, require regular use of calcium preparations to prevent or treat calcium deficiency.
[発明が解決しようとする課題]
かかるカルシウム製剤は、上記のように長期連続服用を
要するため、服用感の良い剤型であることが望ましい。[Problems to be Solved by the Invention] Since such calcium preparations require continuous administration over a long period of time as described above, it is desirable that they be in a dosage form that is comfortable to take.
しかし、カルシウム含量の多い無機系カルシウムを用い
ると、服用すべき製剤量は少なくなるが、無機系カルシ
ウムが刺激性であったり溶解性が悪いため舌ざわりの悪
い製剤となる。However, when inorganic calcium with a high calcium content is used, the amount of the preparation to be taken is reduced, but the inorganic calcium is irritating and has poor solubility, resulting in a preparation with a bad texture.
また、有機系カルシウムを用いると、舌ざわりは良くな
るが、カルシウム含量が少ないため服用すベき製剤量が
多くなり、長期連続服用は困難となる。そこで、無機系
カルシウムと有機系カルシウムの併用により、服用感を
向上すべく努力はされているが、満足し得る効果は得ら
れていない。Furthermore, when organic calcium is used, the texture becomes better on the tongue, but since the calcium content is low, the amount of the preparation that must be taken increases, making it difficult to take it continuously for a long period of time. Therefore, efforts have been made to improve the feeling of taking the drug by using a combination of inorganic calcium and organic calcium, but no satisfactory effect has been achieved.
従って、本発明は味及び服用感が良く、摂取が容易で長
期連続服用に適したカルシウム製剤を提供することを目
的とする。Therefore, an object of the present invention is to provide a calcium preparation that has good taste and feeling, is easy to take, and is suitable for long-term continuous administration.
[課題を解決するための手段]
かかる実情において、本発明者らは鋭意研究を行なった
結果、賦形剤としてキシリトールを用いた発泡性の製剤
が上記課題を解決し得るものであることを見出し、本発
明を完成した。[Means for Solving the Problems] Under these circumstances, the present inventors conducted intensive research and found that an effervescent formulation using xylitol as an excipient can solve the above problems. , completed the invention.
すなわち本発明は、カルシウム塩、キシリトール、有機
酸及び炭酸塩を含有することを特徴とするカルシウム製
剤、並びに炭酸カルシウム、キシリトール及び有機酸を
含有することを特徴とするカルシウム製剤を提供するも
のである。That is, the present invention provides a calcium preparation characterized by containing a calcium salt, xylitol, an organic acid, and a carbonate, and a calcium preparation characterized by containing calcium carbonate, xylitol, and an organic acid. .
本発明において使用し得るカルシウム塩としては、無機
系カルシウムとして塩化カルシウム、リン酸水素カルシ
ウム、沈降炭酸カルシウム、ボレー等が、有機系カルシ
ウムとしてグルコン酸カルシウム、乳酸カルシウム、ア
スパラギン酸カルシウム、グリセロリン酸カルシウム等
が挙げられる。Examples of calcium salts that can be used in the present invention include inorganic calcium such as calcium chloride, calcium hydrogen phosphate, precipitated calcium carbonate, and boley, and organic calcium such as calcium gluconate, calcium lactate, calcium aspartate, and calcium glycerophosphate. Can be mentioned.
これらは単独で、または2種以上を組み合わせて使用す
ることができる。These can be used alone or in combination of two or more.
本発明において、キシリトールは賦形剤として使用され
、その使用量は本発明カルシウム製剤の5〜90重量%
、特に40〜70重量%が好ましい。In the present invention, xylitol is used as an excipient, and the amount used is 5 to 90% by weight of the calcium preparation of the present invention.
, particularly preferably 40 to 70% by weight.
また、本発明において使用し得る有機酸としては、アス
コルビン酸、コハク酸、酒石酸、クエン酸、リンゴ酸、
フマル酸、乳酸、グルコン酸等が挙げられる。これらは
単独で、または2種以上を組み合わせて使用することが
できる。有機酸の使用量は本発明カルシウム製剤に対し
て0.5〜50重量%、特に1〜10重量%が好ましい
。In addition, organic acids that can be used in the present invention include ascorbic acid, succinic acid, tartaric acid, citric acid, malic acid,
Examples include fumaric acid, lactic acid, and gluconic acid. These can be used alone or in combination of two or more. The amount of organic acid used is preferably 0.5 to 50% by weight, particularly 1 to 10% by weight, based on the calcium preparation of the present invention.
更に、本発明において使用し得る炭酸塩としては、炭酸
水素ナトリウム、炭酸カルシウム、炭酸ナトリウム、炭
酸カリウム、炭酸アンモニウム、炭酸マグネシウム等が
挙げられる。これらは単独で、または2種以上を組み合
わせて使用することができる。炭酸塩の使用量は本発明
カルシウム製剤に対して0.5〜50重量%、特に1〜
10重量%が好ましい。なお、カルシウム塩として炭酸
カルシウムを使用する場合は、このもの自体が炭酸塩で
あるので、更に他の炭酸塩を使用する必要はない。Further, carbonates that can be used in the present invention include sodium hydrogen carbonate, calcium carbonate, sodium carbonate, potassium carbonate, ammonium carbonate, magnesium carbonate, and the like. These can be used alone or in combination of two or more. The amount of carbonate used is 0.5 to 50% by weight, especially 1 to 50% by weight, based on the calcium preparation of the present invention.
10% by weight is preferred. Note that when calcium carbonate is used as the calcium salt, since this itself is a carbonate, there is no need to further use another carbonate.
この場合、炭酸カルシウムの使用量は、本発明カルシウ
ム製剤に対して5〜80重量%、特に30〜60重量%
が好ましい。In this case, the amount of calcium carbonate used is 5 to 80% by weight, particularly 30 to 60% by weight, based on the calcium preparation of the present invention.
is preferred.
本発明のカルシウム製剤は種々の剤型とすることができ
るが、摂取の容易性を考慮すると、顆粒剤、細粒剤、錠
剤等の剤型とするのが好ましい。The calcium preparation of the present invention can be made into various dosage forms, but in consideration of ease of ingestion, dosage forms such as granules, fine granules, and tablets are preferred.
本発明のカルシウム製剤には、更に必要に応じてその他
の栄養成分または一般に用いられる賦形剤、結合剤、崩
壊剤、滑沢剤等をその剤型により添加してもよい。賦形
剤としては、デンプン、結晶セルロース、マンニトール
、乳糖、白糖、ソルビトール、デキストリン、軽質無水
ケイ酸等が挙げられる。結合剤としては、セルロース誘
導体、合成高分子化合物等が挙げられ、特にヒドロキシ
プロピルセルロースが好ましい。また、本発明カルシウ
ム製剤の成分の一部または全部を該結合剤でコーティン
グすることが好ましい。崩壊剤としては、デンプン、結
晶セルロース、カルボキシメチルセルロースカルシウム
等が挙げられる。また、錠剤とする場合の滑沢剤として
は、タルク、ステアリン酸、ステアリン酸マグネシウム
、パラフィン等が挙げられる。If necessary, other nutritional ingredients or commonly used excipients, binders, disintegrants, lubricants, etc. may be added to the calcium preparation of the present invention depending on its dosage form. Excipients include starch, crystalline cellulose, mannitol, lactose, sucrose, sorbitol, dextrin, light silicic anhydride, and the like. Examples of the binder include cellulose derivatives and synthetic polymer compounds, with hydroxypropyl cellulose being particularly preferred. Moreover, it is preferable to coat some or all of the components of the calcium preparation of the present invention with the binder. Examples of the disintegrant include starch, crystalline cellulose, carboxymethylcellulose calcium, and the like. In addition, examples of lubricants for tablets include talc, stearic acid, magnesium stearate, paraffin, and the like.
本発明のカルシウム製剤は、例えば次のようにして製造
される。すなわち、カルシウム塩に、キシリトール、有
機酸及び炭酸塩のほか、結合剤、崩壊剤等を加え、常法
により造粒または整粒することにより顆粒剤または細粒
剤が得られる。また、滑沢剤を添加して常法により製錠
することにより錠剤が得られる。The calcium preparation of the present invention is manufactured, for example, as follows. That is, granules or fine granules can be obtained by adding xylitol, an organic acid, a carbonate, a binder, a disintegrant, etc. to a calcium salt, and granulating or sizing the mixture by a conventional method. Further, tablets can be obtained by adding a lubricant and tabletting by a conventional method.
[作用及び発明の効果]
本発明のカルシウム製剤は叙上のごとく構成されている
ので、服用時、発泡による日中での刺激感、発生する炭
酸ガスによるカルシウムの溶解性向上及びキシリトール
の冷涼感により、服用感がよく、摂取が容易であり、特
に長期連用に適している。[Actions and Effects of the Invention] The calcium preparation of the present invention is configured as described above, so that when taken, the foaming causes a feeling of irritation during the day, the carbon dioxide generated improves the solubility of calcium, and the xylitol provides a cooling sensation. Therefore, it has a good feel and is easy to take, and is particularly suitable for long-term use.
[実施例]
以下、実施例を挙げて更に詳細に説明するが、本発明は
これらに限定されるものではない。[Examples] Hereinafter, the present invention will be explained in more detail by giving examples, but the present invention is not limited thereto.
実施例1
沈降炭酸カルシウム1500g、キシリトール2863
.2g及びヒドロキシプロピルセルロース220gを均
一に混合し、エタノールを加えて練合した後、50℃で
乾燥し篩分けして、12号篩通過、42号篩残のものを
得た。これに、流動相コーティング装置を用いて酒石酸
192gにヒドロキシプロピルセルロース20gをコー
ティングしたもの及び香料4.8gを添加し、均一に混
合して顆粒剤を得た。Example 1 Precipitated calcium carbonate 1500g, xylitol 2863
.. 2 g of hydroxypropyl cellulose and 220 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, and then dried at 50° C. and sieved to obtain a product that passed through a No. 12 sieve and remained on a No. 42 sieve. To this, 192 g of tartaric acid coated with 20 g of hydroxypropyl cellulose and 4.8 g of fragrance were added using a fluid phase coating device and mixed uniformly to obtain granules.
用法・容量:1回1包(1,6g) 1日3回服用実施
例2
沈降炭酸カルシウム1500g、塩酸リジン125g。Usage/Capacity: 1 packet (1.6 g) at a time, taken 3 times a day Example 2 Precipitated calcium carbonate 1500 g, lysine hydrochloride 125 g.
アミノエチルスルホン酸75g1エルゴカルシフエロー
ル10■、キシリトール2663 、2g、ヒドロキシ
プロピルセルロース240g及び酒石酸192gを均一
に混合し、エタノールを加えて練合した後、50℃で乾
燥し篩分けして30号篩通過、200号篩残のものを得
た。これに香料4.8gを添加して細粒剤を得た。75g of aminoethylsulfonic acid, 10g of ergocalciferol, 2g of xylitol 2663, 240g of hydroxypropylcellulose and 192g of tartaric acid were mixed uniformly, ethanol was added and kneaded, then dried at 50°C and sieved through a No. 30 sieve. It passed through the sieve, and a No. 200 sieve residue was obtained. 4.8 g of fragrance was added to this to obtain fine granules.
用法・容量:1回1包(1,6g) 1日3回服用実施
例3
リン酸水素カルシウム2576g、キシリトール140
3.2g及びヒドロキシプロピルセルロース240gを
均一に混合し、エタノールを加えて練合した後、50℃
で乾燥し20号篩過した。これに酒石酸、炭酸水素ナト
リウム及びステアリン酸マグネシウム各192g並びに
香料4.8gを添加し、菊水社製ロータリー打錠機を用
いて製錠し、直径15關重さ1.6gのチュアブル錠を
得た。Usage/Capacity: 1 packet (1.6 g) at a time, taken 3 times a day Example 3 Calcium hydrogen phosphate 2576 g, xylitol 140
After uniformly mixing 3.2 g and 240 g of hydroxypropyl cellulose, adding ethanol and kneading, the mixture was heated to 50°C.
It was dried and passed through a No. 20 sieve. To this, 192 g each of tartaric acid, sodium hydrogen carbonate, and magnesium stearate, and 4.8 g of fragrance were added, and tablets were made using a rotary tablet press manufactured by Kikusui Co., Ltd. to obtain chewable tablets with a diameter of 15 mm and a weight of 1.6 g. .
用法・容量=1回1錠1日3回、日中で溶かすか、また
は噛み砕いて服用
実施例4
リン酸水素カルシウム1850g、グルコン酸カルシウ
ム1850g、キシリトール279.2g及びヒドロキ
シプロピルセルロース240gを均一に混合し、エタノ
ールを加えて練合した後、50℃で乾燥し20号篩過し
た。これに酒石酸、炭酸水素ナトリウム及びステアリン
酸マグネシウム各192g並びに香料4.8gを添加し
、菊水社製ロータリー打錠機を用いて製錠し、直径15
mn重さ1.6gのチュアブル錠を得た。Dosage/Capacity: 1 tablet at a time, 3 times a day, dissolve or chew during the day. Example 4: 1850 g of calcium hydrogen phosphate, 1850 g of calcium gluconate, 279.2 g of xylitol, and 240 g of hydroxypropyl cellulose are uniformly mixed together. After adding ethanol and kneading, the mixture was dried at 50°C and passed through a No. 20 sieve. To this was added 192 g each of tartaric acid, sodium hydrogen carbonate, magnesium stearate, and 4.8 g of fragrance, and the tablets were made using a rotary tablet machine manufactured by Kikusui Co., Ltd., with a diameter of 15 mm.
Chewable tablets weighing 1.6 g were obtained.
用法・容量:1回1錠1日3回、日中で溶かすか、また
は噛み砕いて服用
比較例1
沈降炭酸カルシウム1500g、精製白糖3055 、
2g及びヒドロキシプロピルセルロース240gを均一
に混合し、エタノールを加えて練合した後、50℃で乾
燥し篩分けして12号篩通過、42号篩残のものを得た
。これに香料4.8gを添加混合して顆粒剤を得た。Dosage/Capacity: 1 tablet at a time, 3 times a day, dissolve or chew during the day Comparative Example 1 Precipitated calcium carbonate 1500g, refined white sugar 3055g,
2 g of hydroxypropylcellulose and 240 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, and then dried at 50° C. and sieved to obtain a product that passed through a No. 12 sieve and remained on a No. 42 sieve. 4.8 g of fragrance was added and mixed to obtain granules.
比較例2 沈降炭酸カルシウム1500g、塩酸リジン125g。Comparative example 2 1500 g of precipitated calcium carbonate, 125 g of lysine hydrochloride.
アミノエチルスルホン酸75g1エルゴカルシフエロー
ル10mg、 D−vンニトール2855.2g及びヒ
ドロキシプロピルセルロース240gを均一に混合し、
エタノールを加えて練合した後、50℃で乾燥し篩分け
して30号篩通過、200号篩残のものを得た。これに
香料4.8gを添加して細粒剤を得た。75 g of aminoethyl sulfonic acid, 10 mg of ergocalciferol, 2855.2 g of D-vnitol and 240 g of hydroxypropyl cellulose were uniformly mixed,
After adding ethanol and kneading, the mixture was dried at 50°C and sieved to obtain a product that passed through a No. 30 sieve and remained on a No. 200 sieve. 4.8 g of fragrance was added to this to obtain fine granules.
比較例3
リン酸水素カルシウム2576g、乳糖1787.2g
及びヒドロキシプロピルセルロース240gを均一に混
合し、エタノールを加えて練合した後、50℃で乾燥し
20号篩過した。これにステアリン酸マグネシウム19
2g及び香料4,8gを添加し、菊水社製ロータリー打
錠機を用いて製錠し、直径15 m重さ1.6gのチュ
アブル錠を得た。Comparative Example 3 Calcium hydrogen phosphate 2576g, lactose 1787.2g
and 240 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, and the mixture was dried at 50° C. and passed through a No. 20 sieve. This includes magnesium stearate 19
2 g and 4.8 g of fragrance were added, and tablets were made using a rotary tablet press manufactured by Kikusui Co., Ltd. to obtain chewable tablets with a diameter of 15 m and a weight of 1.6 g.
比較例4
リン酸水素カルシウム1850g、グルコン酸カルシウ
ム1850g、精製白糖663.2g及びヒドロキシプ
ロピルセルロース240gを均一に混合し、エタノール
を加えて練合した後、50℃で乾燥し20号篩過した。Comparative Example 4 1850 g of calcium hydrogen phosphate, 1850 g of calcium gluconate, 663.2 g of refined white sugar and 240 g of hydroxypropyl cellulose were uniformly mixed, ethanol was added and kneaded, then dried at 50° C. and passed through a No. 20 sieve.
これにステアリン酸マグネシウム192g及び香料4.
8gを添加し、菊水社製ロータリー打錠機を用いて製錠
し、直径15圓重さ1.6gのチュアブル錠を得た。Add to this 192g of magnesium stearate and 4.
8 g was added and tablets were made using a rotary tablet press manufactured by Kikusuisha Co., Ltd. to obtain chewable tablets with a diameter of 15 circles and a weight of 1.6 g.
試験例1
実施例1〜4及び比較例1〜4で得たカルシウム製剤の
服用感を6名のパネラ−により比較した。Test Example 1 Six panelists compared the feeling of taking the calcium preparations obtained in Examples 1 to 4 and Comparative Examples 1 to 4.
実施例1〜4の本発明カルシウム製剤はいずれも味がよ
く、粉っぽくなく、口当たりが良かったのに対し、比較
例1〜4のカルシウム製剤はいずれも粉っぽく、服用感
が悪かった。The calcium preparations of the present invention in Examples 1 to 4 all had good taste, were not powdery, and had a good texture, whereas the calcium preparations in Comparative Examples 1 to 4 were all powdery and had a poor feeling when taking. .
以上that's all
Claims (5)
を含有することを特徴とするカルシウム製剤。(1) A calcium preparation characterized by containing a calcium salt, xylitol, an organic acid, and a carbonate.
50重量%である請求項1記載のカルシウム製剤。(2) The contents of organic acid and carbonate are each 0.5 to 0.5
The calcium preparation according to claim 1, which is 50% by weight.
することを特徴とするカルシウム製剤。(3) A calcium preparation containing calcium carbonate, xylitol, and an organic acid.
る請求項3記載のカルシウム製剤。(4) The calcium preparation according to claim 3, wherein the content of calcium carbonate is 5 to 80% by weight.
請求項1または3記載のカルシウム製剤。(5) The calcium preparation according to claim 1 or 3, wherein the content of xylitol is 5 to 90% by weight.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1226216A JP2616822B2 (en) | 1989-08-31 | 1989-08-31 | Calcium preparation |
CA002023493A CA2023493C (en) | 1989-08-31 | 1990-08-17 | Composition for foaming preparation |
KR1019900013153A KR100187951B1 (en) | 1989-08-31 | 1990-08-24 | Composition for foaming preparation |
DE69012932T DE69012932T2 (en) | 1989-08-31 | 1990-08-27 | Preparation for foaming preparation. |
EP90116398A EP0415326B1 (en) | 1989-08-31 | 1990-08-27 | Composition for foaming preparation |
US07/806,791 US5204087A (en) | 1989-08-31 | 1991-12-12 | Composition for foaming preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1226216A JP2616822B2 (en) | 1989-08-31 | 1989-08-31 | Calcium preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0390030A true JPH0390030A (en) | 1991-04-16 |
JP2616822B2 JP2616822B2 (en) | 1997-06-04 |
Family
ID=16841716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1226216A Expired - Lifetime JP2616822B2 (en) | 1989-08-31 | 1989-08-31 | Calcium preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2616822B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013539768A (en) * | 2010-10-13 | 2013-10-28 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Phosphate binder formulation for easy administration |
JP2015073611A (en) * | 2013-10-07 | 2015-04-20 | アース製薬株式会社 | Aromatic |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61207322A (en) * | 1985-03-11 | 1986-09-13 | Sunstar Inc | Foamable solid composition containing ascorbic acid |
JPS6289616A (en) * | 1985-10-16 | 1987-04-24 | Kao Corp | Tablet production |
-
1989
- 1989-08-31 JP JP1226216A patent/JP2616822B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61207322A (en) * | 1985-03-11 | 1986-09-13 | Sunstar Inc | Foamable solid composition containing ascorbic acid |
JPS6289616A (en) * | 1985-10-16 | 1987-04-24 | Kao Corp | Tablet production |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013539768A (en) * | 2010-10-13 | 2013-10-28 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Phosphate binder formulation for easy administration |
JP2015073611A (en) * | 2013-10-07 | 2015-04-20 | アース製薬株式会社 | Aromatic |
Also Published As
Publication number | Publication date |
---|---|
JP2616822B2 (en) | 1997-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5753254A (en) | Therapeutic agents containing thyroid hormones | |
KR950009090B1 (en) | Pharmaceutical composition containing ibuprofen and aluminium hydroxide | |
JP2546068B2 (en) | Preparation containing L-carnitine | |
KR100898970B1 (en) | Particulate comprising a calcium-containing compound and a sugar alcohol | |
PT1660104E (en) | Pharmaceutical formulation comprising lanthanum compounds | |
JPS63211224A (en) | Water-dispersible tablet | |
US5432200A (en) | Method for increasing urinary excretion of electrolytes | |
JP2016174616A (en) | Disintegrable composition, and easily disintegrable compression molding | |
DK169605B1 (en) | Magnesium additive for food, feed and pharmaceuticals | |
KR100187951B1 (en) | Composition for foaming preparation | |
JP4501024B2 (en) | Composition with reduced bitterness and odor of cysteines | |
JP2995226B2 (en) | Chewable tablets containing calcium | |
JPH0559090B2 (en) | ||
JPH01151515A (en) | Treatment of osteoporosis and related disorder | |
JP5168712B2 (en) | Nateglinide-containing preparation | |
JPH09502709A (en) | Oral, water-soluble pharmaceutical composition containing estrone derivative and calcium salt | |
JPH0390030A (en) | Calcium preparation | |
JP3067125B2 (en) | Easy-to-take nucleated tablet-type preparation | |
US5204087A (en) | Composition for foaming preparation | |
JP6554034B2 (en) | Calcium agent | |
JPH09169651A (en) | Vitamin-containing tablet and its production | |
CA1326040C (en) | Magnesium-potassium citrate | |
HU211084B (en) | Process for producing oral pharmaceutical composition of bone strengthening activity | |
JP2009137872A (en) | Glucuronolactone-containing solid preparation for oral use | |
JP3545512B2 (en) | Effervescent tablets containing crude drugs |